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Background: With the development of more conformal and precise radiation techniques such as Intensity-Modulated
Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT) and Image-Guided Radiotherapy (IGRT), patients with
hepatic tumors could be treated with high local doses by sparing normal liver tissue. However, frequently occurring
large HCC tumors are still a dosimetric challenge in spite of modern high sophisticated RT modalities. This interventional
clinical study has been set up to evaluate the value of different fiducial markers, and to use the modern imaging
methods for further treatment optimization using physical and informatics approaches.
Methods and design: Surgically implanted radioopaque or electromagnetic markers are used to detect tumor
local-ization during radiotherapy. The required markers for targeting and observation during RT can be implanted
in a previously defined optimal position during the oncologically indicated operation. If there is no indication for
a surgical resection or open biopsy, markers may be inserted into the liver or tumor tissue by using ultrasound-guidance.
Primary study aim is the detection of the patients´ anatomy at the time of RT by observation of the marker position
during the indicated irradiation (IGRT). Secondary study aims comprise detection and recording of 3D liver and tumor
motion during RT. Furthermore, the study will help to develop technical strategies and mechanisms based on the
recorded information on organ motion to avoid inaccurate dose application resulting from fast organ motion
and deformation.
Discussion: This is an open monocentric non-randomized, prospective study for the evaluation of organ motion
using interstitial markers or implantable radiotransmitter. The trial will evaluate the full potential of different fiducial
markers to further optimize treatment of moving targets, with a special focus on liver lesions.
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Primary liver tumors (PLC) represent a great challenge in
radiooncology because tumor sizes are often large and
represent a relatively high proportion of liver tissue [1].
Furthermore, high radiation doses are needed for long-
term control of primary liver cancer. Incidence of hepato-
cellular carcinoma (HCC) is raising in western countries
mostly due to increasing hepatitis c infections. Current
therapeutic approaches for HCC and other PLC are
complete surgical resection, liver transplantation and
locoregional ablative therapies including radiofrequency
ablation and chemoembolization. In case of locally ad-
vanced or metastasized tumors the multi-kinase inhibitor
Sorafenib (Nexavar®) has proven efficacy and leads to pro-
longed overall survival compared to placebo [2].
Radiation therapy has failed to show promising results
in the past because conventional photon techniques lead
to a high dose deposition in the normal liver which can
potentially cause Radiation-Induced Liver Disease (RILD)
[3]. With the development of more conformal and precise
radiation techniques such as Intensity-Modulated Radio-
therapy (IMRT), Stereotactic Body Radiotherapy (SBRT)
and Image-Guided Radiotherapy (IGRT) over the last two
decades, patients with hepatic tumors (mainly not suitable
for standard therapies) could be treated with high local
doses by sparing normal liver tissue and showed good
short- and long-term responses [4–7]. However, fre-
quently occurring large HCC tumors are still a dosimet-
ric challenge in spite of modern high sophisticated RT
modalities due to the limited hepatic tolerance and lim-
ited hepatic function in this patient subgroup with a
high frequency of liver cirrhosis [4, 8].
Treatment of PLC and liver metastases is an interdis-
ciplinary challenge for all involved clinical disciplines.
While multiple liver metastases are treated with systemic
therapies, oligometastatic patients can undergo local ab-
lative treatment approaches, e. g. surgical resection, RFA
and radiotherapy (RT) [5, 9]. Every local ablative ap-
proach has pros and cons and clinical decision finding
depends on tumor localization, size, proximity to greater
vessels and multifocality. In many cases different therapy
modalities have to be combined to achieve optimal re-
sults. Radiotherapy may play a more important role in
centrally located tumors near the porta hepatica, in case
of close proximity to the portal or hepatic vein, local re-
lapses or medically inoperable patients.
There are numerous studies on the characterization of
respiration-induced tumor motion [10–13]. Attempts to
detect tumor motion through the analysis of easily ob-
servable surrogate signals (e. g. Anzai-belt, lung volume)
finally showed a relatively high grade of uncertainty. Sev-
eral feasibility studies focused on fiducial- or image-
based recognition of organ and tumor motion [14, 15].
These publications showed that the use of radioopaquefiducial markers can successfully minimize margins, in-
crease dose to tumor volume and finally improve clinical
results [16].
Dynamic adaptation of dose application due to de-
tection of real-time organ motion requires the predic-
tion of organ motion during time latency of the
individual system. A further unsolved problem is the
prediction of organs at risk (OARs) during therapy. To
compensate for inaccurate irradiation due to organ
motion during therapy with a conventional linear ac-
celerator (LINAC) mainly two strategies are possible:
adaptation of tumor position through dynamic couch
shifting and automatic adaptation of the multi-leaf
collimator (MLC). None of these strategies has been
successfully integrated in clinical routine. Besides the
prediction of respiratory-induced motion another un-
resolved issue is the secure integration of a real-time
motion sensor with an automatic, dynamic MLC con-
formation into one system.
Surgically implanted radioopaque or electromagnetic
markers are used to detect tumor localization during
radiotherapy. Radioopaque markers are commercially
available and approved as medical product. The elec-
tromagnetic markers of the CALYPSO system in the
U.S. are approved by the Federal Drug Administration
(FDA). The surgical implantation follows a preceding
interdisciplinary discussion for the definition of an
oncological therapy concept with the aim of extract-
ing a biopsy or a surgical resection of the tumor in
one session. The required markers for targeting and
observation during RT can be implanted in a previ-
ously defined optimal position during the oncologi-
cally indicated operation. If there is no indication for
a surgical resection or biopsy (open biopsy), markers
may be inserted into the liver/tumor tissue by using
ultrasound-guidance.
Thus, the present study concept has been set up to
evaluate the value of different fiducial markers, and to use
the aquired imaging for further treatment optimization
using physical and informatics approaches.
Methods and design
Primary and secondary study aims
Primary study aim is the detection of the patients´
anatomy at the time of RT by observation of the
marker position during the oncologically indicated ir-
radiation (IGRT).
Secondary study aims
– Detection and recording of 3D organ motion of the
liver during RT
– Development of technical strategies and
mechanisms based on the recorded information on
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resulting from fast organ motion and deformation
Study design
The study is a prospective, single-armed, non-randomized
clinical trial.
Therapeutic advantages for patients included in the
clinical trial and treatment
The immediate advantage for all patients who will par-
ticipate in the present trial consists in the procedure of
marker implantation for the detection of organ motion
before radiotherapy. The radioopaque marker material
allows correlation of IGRT generated kV- or MV-based
cone-beam-CTs with pretherapeutic treatment planning
CT scans and thus provides additional information that
improves the accuracy of patient positioning and dose
application. For this purpose medically approved interstitial
fiducial markers (CE labeled) are applied for clinical use,
and furthermore the electromagnetic CALYPSO marker
system has FDA approval for comparable indications.
For local ablative treatments a three to eight frac-
tion regimen, e.g. 3×20 Gy (primarily liver tumors) or
8×7.5 Gy(centrally located lung tumors) prescribed to
the 65- or 80 %-isodose will be performed. Conven-
tional doses are not planned for patients included in
the ESMERALDA-trial. Currently, patients are immo-
bilized using a customized vacuum pillow and an ab-
dominal compression. However, if patients don´t
tolerate the compression a free-breathing radiotherapy
will be performed, e.g. with a gating technique. Treat-
ment planning will be performed using a 4D-CT scan
and free breathing; breath-hold techniques are not
establied at our institution. Fiducial marker (except
the Calypso system) motion will be analyzed by infor-
mation derived from the 4D computed tomography of
the treatment planning imaging, fluoroscopic imaging
in the treatment position/setup and the sequential
and interfractional kV-CBCT imaging.
Toxicity and additional radiation exposure for patients
Implanted markers are approved for clinical use in this
setting. There will be no toxicities that exceed the
known toxicities resulting from the implantation proced-
ure. In the context of IGRT portal images will be taken
regularly and no additional radiation exposure will
occur. Through the observation of the marker position
and the installation of the monitor system (e.g. Calypso
system), there will be an additional time effort of about
15-20 minutes for the patient.
Study design
This is an open monocentric non-randomized, prospective
study for the evaluation of organ motion using interstitialmarkers or implantable radiotransmitter for the treatment
of liver tumors.
Randomization
None.
Inclusion criteria
 Indication for high precision radiotherapy of
primary and secondary liver tumors using IGRT
 Age ≥ 18 years of age
 ability of subject to understand character and
individual consequences of the clinical trial
 written informed consent (must be available before
enrolment in the trial)
Exclusion criteria
 refusal of the patients to take part in the study
 medical reasons impeding marker implantation or
IGRT for treatment of liver tumors.
 non-compliance of patients
Study plan and duration of regular study participation
1. Interdisciplinary consent for the indication of high
precision RT of primary or secondary liver tumors
2. Information about the ESMERALDA study with a
focus on trial sequence, risks and adverse events
3. Submission of the written informed consent
4. Implantation of the required fiducial markers for
IGRT in the context of an oncologically indicated
operation or during an ultrasound-guided procedure
5. Imaging studies for radiotherapy treatment planning
6. Radiotherapy treatment planning
7. Radiotherapy with daily IGRT and/or the CALYPSO
system
8. Planned study end: 6-8 weeks after the end of RT
(first oncolgical follow-up)
Acquired data will be pseudonymised for further tech-
nical examinations and computations.
Concomitant therapies
n/a
Study duration
The recruiting phase of the study will end after inclusion
of the planned patient number of n = 50.
Premature study end
New scientific findings may lead to a premature end of
the study. Decision on study closing will be made by all
participating persons.
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This prospective, non-randomized clinical trial is planned
to include 50 patients with primary (n = 25) or secondary
(n = 25) liver tumors. The proposed number of patients is
an approximated estimation for a sufficient investigation
of parameters in both groups which allows a finalization
during the mentioned timeline. A dedicated power calcu-
lation is not adequate and was therefore not performed.
Motion data of the initial 4D treatment planning CT will
be correlated with on-board fluoroscopic and CBCT-
based motion and calculated shift vectors. Intrafraction as
well as interfraction motion will be measured. Further-
more, putative fiducial migration will be analyzed. In
summary, the study will help to establish a motion-
management strategy, also including the significance of
the number of markers and their spatial correlation.
Ethical and legal aspects
Declaration of helsinki
The study is in compliance with the Declaration of
Helsinki (2008 Version of the Declaration of Helsinki,
adopted at the 59th WMA General Assembly, Seoul,
October 2008).
Ethical aspects
The study protocol as well as the patients´ informed con-
sent and the patient information were submitted to the
Ethical Commission of the University of Heidelberg for
appraisal. The assigned in-house number is S-112/2012.
All changes of the study protocol, especially those con-
cerning patient safety, will be communicated to the study
committee of the Ethical Commission.
Patients´ informed consent
Only those patients who agreed to participate in the
study after detailed oral and written information will be
included. Study participation is voluntary and can be
withdrawn at any time by the patients´ choice without
any reasons.
Funding
This study protocol has not undergone peer-review by a
funding body.
Study registration
The study is registered on clinicaltrials.gov with the fol-
lowing ID: NCT02095236.
Status of the study
The study is currently recruiting patients.
Discussion
From a radiation oncology perspective, optimization of
dose distributions as well as motion management inmoving targets is of utmost priority. For the latter, mo-
tion surrogates can be implemented, such as fiducial
markers placed into the tumor or into its surrounding
tissue. The present one-armed non-randomized trial will
evaluate the full potential of different fiducial markers to
further optimize treatment of moving targets, with spe-
cial focus on liver lesions.
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